Amicus Therapeutics is a Cranbury, New Jersey based biopharmaceutical company who specializes in rare and orphan diseases. The company was started in February of 2002 and has made a successful climb through the market place since its establishment. Amicus Therapeutics leader is Chief Executive Officer and Chairman of the Board John F. Crowley, who has worked diligently with the company since 2004.
The field of biopharmaceuticals is large and diverse. Amicus Therapeutics works with a focused goal of finding cures for specific rare diseases, more specifically lysosomal storage disorders (LSD). LSD is a group of about 50 rare diseases that are caused by defects in the lysosomal function. In the large scale of biopharmaceuticals LSD is a small area of study, but to the employees of Amicus Therapeutics, it is the most important work that they do to help those in the most need.
With their focus and dedication to these scientific pursuits, Amicus has been able to gain grants and collaboration with other passionate people in the industry. In 2010, they received a half million dollar grant from The Michael J. Fox Foundation as well as a more than $210,000 grant from Alzheimer’s Drug Discovery Foundation (YahooFinance). Both of these monetary contributions have helped Amicus Therapeutics continue their study while also collaborating with the UCLA David Geffen School of Medicine and with Icahn School of Medicine at Mount Sinai. In 2013 the company was able to acquire Callidus Biopharma which encompassed an important therapy treatment for Pompe disease.
Gaining the intellectual property and proprietary materials for this particular treatment held a lot of personal value for Amicus Therapeutics CEO John F. Crowley. Crowley has two children who had been diagnosed with Pompe in 1998. He worked to support his family while also immersing himself in the study of treatments for his children and the disease. His passion and dedication to Amicus Therapeutics goes far beyond having a good career, he works for his company to advance the research that can save lives, including those of his children. Crowley brings his own personal drive and experiences that help keep the companies focus on truly help those individuals, and families, who suffer from LSD.
More about Amicus Therapeutics at http://weeklyopinion.com/2017/08/amicus-therapeutics-announces-the-launch-of-new-drug/